Status: 07/28/2021 2:58 p.m.
The success of the Covid vaccine developed by BioNTech has exceeded all expectations. The American pharmaceutical giant and BioNTech partner Pfizer has drastically increased its sales forecast.
The Covid-19 vaccine, marketed together with the German company BioNTech, makes the tills ring at Pfizer. The US pharmaceutical company now expects sales of 33.5 billion dollars this year with the vaccine Comirnaty alone. Most recently, Pfizer had assumed around $ 26 billion. Since then, the partners have concluded further supply contracts.
The new estimate is based on the currently signed supply contracts for around 2.1 billion vaccine doses for 2021, Pfizer announced on Wednesday. In total, Pfizer and Mainz-based BioNTech want to produce three billion doses of the vaccine this year.
Quarterly profit increased by 60 percent
This also has a significant impact on the annual targets of the US pharmaceutical giant: Pfizer is now predicting an increase in annual sales to 78 to 80 billion dollars, after previously targeting 70.5 to 72.5 billion. Adjusted earnings per share are expected to reach $ 3.95 to $ 4.05. The old forecast was $ 3.55 to $ 3.65.
In the second quarter, the global vaccination campaigns, in which the drug Comirnaty plays an important role, drove the growth of the US group vigorously: At almost 19 billion dollars, sales almost doubled compared to the previous year. The bottom line was that Pfizer made just under $ 5.6 billion. That was an increase of around 60 percent.